Healthcare Triangle Acquires Health Data Analytics for $15M

TL;DR

HTRI buying HDAI for $15M to boost healthcare data analytics.

AI Summary

Healthcare Triangle, Inc. announced on December 4, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Health Data Analytics, Inc. for an aggregate purchase price of $15 million. The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.

Why It Matters

This acquisition is expected to expand Healthcare Triangle's capabilities in data analytics within the healthcare sector, potentially leading to new service offerings and revenue streams.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies.

Key Numbers

• $15.0M — Acquisition Price (Aggregate purchase price for Health Data Analytics, Inc.)

Key Players & Entities

• Healthcare Triangle, Inc. (company) — Registrant
• Health Data Analytics, Inc. (company) — Acquisition Target
• $15 million (dollar_amount) — Aggregate Purchase Price
• December 4, 2024 (date) — Announcement Date
• First quarter of 2025 (date) — Expected Closing Period

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share HCTI The Nasdaq Stock Mar
• $1.00 — d not maintained a minimum bid price of $1.00 per share, required for continued listi

Filing Documents

• ea0223689-8k_healthcare.htm (8-K) — 26KB
• 0001213900-24-105599.txt ( ) — 198KB
• hcti-20241204.xsd (EX-101.SCH) — 3KB
• hcti-20241204_lab.xml (EX-101.LAB) — 33KB
• hcti-20241204_pre.xml (EX-101.PRE) — 22KB
• ea0223689-8k_healthcare_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events As previously reported, on June 26, 2024, Healthcare Triangle, Inc. (the "Company") received a written notice from the staff (the "Staff") of the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), notifying the Company that, for the 30 consecutive business day period, the Company's common stock, $0.00001 par value per share (the "Common Stock"), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The letter also indicated that the Company had a compliance period of 180 calendar days, or until December 23, 2024, in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A). The letter further provided that if, at any time during the 180-day period, the closing bid price of the Company's common stock was at least $1.00 for a minimum of 10 consecutive business days, the Staff would provide the Company with written confirmation that it had achieved compliance with the Minimum Bid Price Requirement. On December 4, 2024, the Company received a letter from the Staff notifying the Company that for the last 20 consecutive business days, from October 28, 2024 to November 22, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater and, therefore, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and this matter is now closed.

Forward Looking Statements

Forward Looking Statements This Current Report contains forward-looking statements that involve risks and uncertainties intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of current or historical fact contained in this Current Report, including statements regarding the Company's expected timeline for compliance with the Nasdaq's Corporate Governance Rules, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. The Company has based these forward-looking statements on the current expectations about future events held by management. While the Company believes these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company's control. The Company's actual future results may differ materially from those discussed here for various reasons. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this Current Report are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Healthcare Triangle, Inc. Date: December 4, 2024 By: /s/ Thyagarajan Ramachandran Name: Thyagarajan Ramachandran Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR